Cencora Q2 Earnings Call Highlights
- π Cencora reported higher Q2 adjusted earnings and operating income while raising its full-year adjusted EPS outlook.
- π° The company resumed opportunistic share repurchases and highlighted resilience in both U.S. and International Healthcare Solutions segments.
- π Full-year revenue growth expectations were lowered due to faster-than-expected brand conversions at a major mail-order pharmacy customer and slower anticipated GLP-1 product growth.
- π¨βπΌ CEO Bob Mauch noted that investments in the pharmaceutical supply chain are enabling the company to capitalize on key growth opportunities.
- π΅ Adjusted diluted EPS reached $4.75, representing a 7.5% increase year-over-year compared to the prior quarter.
- π¦ Consolidated revenue grew 4% to $78.4 billion, driven by growth across all reportable segments and the "other" category.
- π’ Adjusted consolidated gross profit climbed 16% to $3.4 billion with a gross profit margin expansion of 45 basis points.
- π₯ The margin increase was primarily attributed to the February 2026 acquisition of OneOncology.
- πΈ Operating expenses rose 22.5% overall but grew only 5% on a constant-currency basis excluding management services organizations.
- π Net interest expense increased $36 million year-over-year to $140 million due to debt raised to finance the OneOncology acquisition.
- πΊπΈ U.S. Healthcare Solutions revenue rose 3% to $68.8 billion, led by $1.9 billion in growth from GLP-1 sales.
- β οΈ U.S. growth was tempered by a $2 billion headwind from manufacturer list price reductions and the loss of key oncology and grocery customers in fiscal 2025.
- π§οΈ Inclement weather caused a $10 million operating income headwind in late January and early February due to missed patient appointments.
- π COVID-19 vaccine contributions were down by $10 million compared to the prior-year quarter, offsetting some growth potential.
- π International Healthcare Solutions revenue increased 13% year-over-year to $7.6 billion, primarily driven by European distribution business.
- π Global specialty logistics delivered a second consecutive quarter of operating income growth aided by a rebound in developing markets.
- 𧬠The company is winning new contracts for complex specialty products like cell and gene therapies, leveraging its global reach.
- πΎ Revenue in the "other" category grew 5% to $2.1 billion, largely fueled by growth at Profarma and MWI Animal Health.
- π Operating income in the "other" category declined 1% to $92 million due to an expected decline from legacy U.S. hub consulting services.
- π° The company ended March with $2.2 billion in cash after generating $1.1 billion of free cash flow during the quarter.
- π― Management maintained its full-year adjusted free cash flow guidance of approximately $3 billion despite market fluctuations.
- Cencora reported higher fiscal second-quarter adjusted earnings and operating income, demonstrating resilience despite market headwinds.
- Management raised its full-year adjusted EPS outlook, signaling strong confidence in the company's performance for fiscal 2026.
- The company announced it would resume opportunistic share repurchases, highlighting a commitment to returning value to shareholders.
- Adjusted diluted EPS grew by 7.5% year-over-year to $4.75, driven by growth in both U.S. and International Healthcare Solutions segments.
- Consolidated revenue rose 4% to $78.4 billion, reflecting strong volume growth across both reportable segments.
- Adjusted consolidated gross profit increased 16% to $3.4 billion, with the gross profit margin expanding 45 basis points to 4.31%.
- The company generated $2.2 billion in cash and produced $1.1 billion of free cash flow during the quarter.
- Cencora maintained its full-year adjusted free cash flow guidance of approximately $3 billion, validating its cash generation capabilities.
- U.S. Healthcare Solutions saw $1.9 billion of year-over-year growth specifically from GLP-1 sales.
- International Healthcare Solutions revenue increased 13% to $7.6 billion, with operating income rising 14% to $176 million.
- The International segment delivered its second consecutive quarter of operating income growth, driven by a rebound in European distribution and specialty logistics.
- Cencora is winning new specialty logistics contracts in high-growth areas like cell and gene therapies and laboratory logistics.
- Revenue in the "other" category rose 5% to $2.1 billion, driven by growth at Profarma and MWI Animal Health.
- Cencora lowered its full-year revenue growth expectations due to faster-than-anticipated brand conversions at a large mail-order pharmacy customer, which weighs on revenue more than expected and concentrates the effect on low-margin sales.
- A $2 billion revenue headwind in the quarter stemmed from manufacturer list price reductions.
- Cencora continues to face the impact of previously disclosed fiscal 2025 customer losses for both an oncology client and a grocery customer, with the oncology loss remaining larger than the contribution from the February 2026 OneOncology acquisition during the quarter.
- Inclement weather across the U.S. in late January and early February led to missed patient appointments and lower physician office volumes, creating an estimated $10 million operating income headwind.
- COVID-19 vaccines contributed a negative $10 million to operating income compared with a $15 million contribution in the prior-year quarter.
- Legacy U.S. hub consulting services are expected to decline in revenue following Cencora's divestiture on April 30, causing operating income in the 'other' category to fall 1% to $92 million.